TECX Stock Analysis: Buy, Sell, or Hold?
TECX - Tectonic Therapeutic, Inc. Common Stock
$34.91
0.93 (2.74%)
▲
5d:
+12.69%
30d:
+13.9%
90d:
+17.15%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When TECX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TECX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TECX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TECX is currently trading at $34.91, which is considered extended relative to its 30-day fair value range of $29.42 to $34.29.
Technical Outlook: Technically, TECX is in a uptrend. Immediate support is located at $27.30, while resistance sits at $37.40.
Market Sentiment: TECX scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $77.56 (+128.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TECX is in a uptrend. Immediate support is located at $27.30, while resistance sits at $37.40.
Market Sentiment: TECX scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $77.56 (+128.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$29.42 -
$34.29
Company Quality Score
39/100
(SELL)
Options IV Signal
30th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
35.4%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 30th percentile)
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 128.2% below Wall St target ($77.56)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$29.42 -
$34.29
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$5.52
(15.8%)
Support & Resistance Levels
Support Level
$27.31
Resistance Level
$37.40
Current Trend
Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.22
Wall Street Target
$77.56
(+128.2%)
Share & Embed Analysis
Last updated: August 16, 2026 2:51 AM ET
Data refreshes hourly during market hours. Next update: 3:51 AM
Data refreshes hourly during market hours. Next update: 3:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TECX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Marcella K Ruddy
SELL
1000 shares
2026-04-01
Marcella K Ruddy
SELL
10000 shares
2026-03-06
Peter Mcnamara
SELL
6262 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 43 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1086 | 54 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 47 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 27 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 60 BUY |
